View Future GrowthTelomir Pharmaceuticals 過去の業績過去 基準チェック /06Telomir Pharmaceuticalsの収益は年平均-41.1%で減少しているが、Pharmaceuticals業界はgrowingで8.7%年平均の収益となった。主要情報-41.10%収益成長率-34.15%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率n/a株主資本利益率-176.10%ネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesTelomir Pharmaceuticals, Inc., Annual General Meeting, Mar 23, 2026Feb 21Telomir Pharmaceuticals, Inc. Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer ModelsFeb 19Telomir Pharmaceuticals Receives Non-Compliance Notice from NasdaqJan 13Telomir Pharmaceuticals, Inc. Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal ModelsJan 06Telomir Pharmaceuticals, Inc. Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-In-Human Clinical DevelopmentDec 20Telomir Pharmaceuticals Inc. Announces Resignation of Craig Eagle as Director, Effective on November 14, 2025Nov 22+ 2 more updatesNew minor risk - Shareholder dilution Nov 17Telomir Pharmaceuticals, Inc. Reports New Preclinical Data Demonstrating That Its Lead Investigational Compound Telomir-1 Producing A Strong, Dose-DFONov 12Telomir Pharmaceuticals, Inc. Reports New Data Showing Telomir-1 Resets Cancer's Kill-and-Clean Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and ChemoOct 23Telomir Pharmaceuticals, Inc. Announces New Laboratory Findings Demonstrating That Telomir-1 Reduced the Survival of Aggressive Human Pancreatic Cancer Cells in VitroOct 15Telomir Pharmaceuticals, Inc. Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer CellsOct 09Telomir Pharmaceuticals, Inc. Announces New Cancer Results from Preclinical Studies of Its Lead Investigational Compound, Telomir-1, in Aggressive Prostate Cancer ModelsOct 07Telomir Pharmaceuticals, Inc. Announces New in Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase FamilySep 19Telomir Pharmaceuticals, Inc. Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2ASep 09New major risk - Financial position Aug 15Telomir Pharmaceuticals, Inc. Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer CellsJul 18Telomir Pharmaceuticals, Inc.(NasdaqCM:TELO) dropped from Russell 2500 Growth IndexJun 30+ 16 more updatesTelomir Pharmaceuticals, Inc. Announces Positive New Preclinical Data Demonstrating the Cellular Protective Activity of its Lead Candidate, Telomir-1, in Human Progeria Cell LinesJun 19Telomir Pharmaceuticals Announces Significant Improvements in Neurological, Liver, and Kidney Functions with Telomir-1 in Wilson’S Disease Animal ModelJun 12Telomir Pharmaceuticals, Inc. Announces New Data from A Preclinical Study of Its Lead Compound, Telomir-1Jun 06Telomir Pharmaceuticals, Inc. Provides an Update on the Continued Progress of Its Lead Candidate, Telomir-1Jun 03Telomir Pharmaceuticals, Inc. Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Deegeneration Animal Model Using FDA-Recognized Surrogate EndpointsMay 29New major risk - Financial position May 15New minor risk - Market cap size Apr 01Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer CellsMar 22Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking A Multi-Billion-Dollar Medical MarketFeb 22Telomir Pharmaceuticals, Inc. Auditor Raises 'Going Concern' DoubtFeb 06Telomir Pharmaceuticals Announces Breakthrough Results with Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as A Treatment for Avian Influenza (Bird Flu) and Other VirusesJan 30Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of ProgeriaJan 08+ 1 more updateTelomir Pharmaceuticals, Inc. Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline into Wilson's DiseaseDec 24Telomir Pharmaceuticals, Inc. Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study with Telomir-1Dec 03New minor risk - Market cap size Nov 19New major risk - Financial position Nov 13Telomir Pharmaceuticals, Inc. Appoints Itzchak Angel as Chief Scientific AdvisorSep 04Telomir Pharmaceuticals, Inc. Announces CEO ChangesAug 13+ 1 more updateWill Telomir Pharmaceuticals (NASDAQ:TELO) Spend Its Cash Wisely?Aug 09New minor risk - Market cap size Aug 04Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1Jun 02Telomir Pharmaceuticals, Inc. Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.CApr 18Telomir Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis, Esq. as the General Counsel and A Member of the Board of DirectorsApr 14Telomir Pharmaceuticals Presents Promising Pre-Clinical Data for Its Lead Development Product At Singapore ConferenceMar 08High number of new and inexperienced directors Feb 10収支内訳Telomir Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:TELO 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 250-108230 Sep 250-1110130 Jun 250-1615131 Mar 250-1211231 Dec 240-1710230 Sep 240-238230 Jun 240-194231 Mar 240-193231 Dec 230-132230 Sep 230-42230 Jun 230-30231 Mar 230-10131 Dec 220-101質の高い収益: TELOは現在利益が出ていません。利益率の向上: TELOは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: TELOは利益が出ておらず、過去 5 年間で損失は年間41.1%の割合で増加しています。成長の加速: TELOの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: TELOは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -3.3% ) と比較することは困難です。株主資本利益率高いROE: TELOは現在利益が出ていないため、自己資本利益率 ( -176.1% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 17:02終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Telomir Pharmaceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Bradley SorensenZacks Small-Cap Research
Telomir Pharmaceuticals, Inc. Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer ModelsFeb 19
Telomir Pharmaceuticals, Inc. Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal ModelsJan 06
Telomir Pharmaceuticals, Inc. Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-In-Human Clinical DevelopmentDec 20
Telomir Pharmaceuticals Inc. Announces Resignation of Craig Eagle as Director, Effective on November 14, 2025Nov 22+ 2 more updates
Telomir Pharmaceuticals, Inc. Reports New Preclinical Data Demonstrating That Its Lead Investigational Compound Telomir-1 Producing A Strong, Dose-DFONov 12
Telomir Pharmaceuticals, Inc. Reports New Data Showing Telomir-1 Resets Cancer's Kill-and-Clean Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and ChemoOct 23
Telomir Pharmaceuticals, Inc. Announces New Laboratory Findings Demonstrating That Telomir-1 Reduced the Survival of Aggressive Human Pancreatic Cancer Cells in VitroOct 15
Telomir Pharmaceuticals, Inc. Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer CellsOct 09
Telomir Pharmaceuticals, Inc. Announces New Cancer Results from Preclinical Studies of Its Lead Investigational Compound, Telomir-1, in Aggressive Prostate Cancer ModelsOct 07
Telomir Pharmaceuticals, Inc. Announces New in Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase FamilySep 19
Telomir Pharmaceuticals, Inc. Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2ASep 09
Telomir Pharmaceuticals, Inc. Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer CellsJul 18
Telomir Pharmaceuticals, Inc.(NasdaqCM:TELO) dropped from Russell 2500 Growth IndexJun 30+ 16 more updates
Telomir Pharmaceuticals, Inc. Announces Positive New Preclinical Data Demonstrating the Cellular Protective Activity of its Lead Candidate, Telomir-1, in Human Progeria Cell LinesJun 19
Telomir Pharmaceuticals Announces Significant Improvements in Neurological, Liver, and Kidney Functions with Telomir-1 in Wilson’S Disease Animal ModelJun 12
Telomir Pharmaceuticals, Inc. Announces New Data from A Preclinical Study of Its Lead Compound, Telomir-1Jun 06
Telomir Pharmaceuticals, Inc. Provides an Update on the Continued Progress of Its Lead Candidate, Telomir-1Jun 03
Telomir Pharmaceuticals, Inc. Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Deegeneration Animal Model Using FDA-Recognized Surrogate EndpointsMay 29
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer CellsMar 22
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking A Multi-Billion-Dollar Medical MarketFeb 22
Telomir Pharmaceuticals Announces Breakthrough Results with Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as A Treatment for Avian Influenza (Bird Flu) and Other VirusesJan 30
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of ProgeriaJan 08+ 1 more update
Telomir Pharmaceuticals, Inc. Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline into Wilson's DiseaseDec 24
Telomir Pharmaceuticals, Inc. Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study with Telomir-1Dec 03
Telomir Pharmaceuticals, Inc. Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.CApr 18
Telomir Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis, Esq. as the General Counsel and A Member of the Board of DirectorsApr 14
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data for Its Lead Development Product At Singapore ConferenceMar 08
